Medical University of South Carolina - Hollings Cancer Center
Welcome,         Profile    Billing    Logout  
 29 Trials 
66 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnson, David H
OpTION, NCT02667418: Optimal Treatment for Recurrent Clostridium Difficile

Recruiting
4
549
US
Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin
VA Office of Research and Development
Clostridium, Difficile, Fidaxomicin, Vancomycin
08/24
08/24
TIGeR-PaC, NCT03257033: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Recruiting
3
320
Europe, US
Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath, RenovoCath RC120
RenovoRx
Locally Advanced Pancreatic Cancer
09/22
09/23
NCT05171673: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury

Recruiting
3
150
US
Licart™ (diclofenac epolamine) topical system, diclofenac epolamine
IBSA Institut Biochimique SA
Soft Tissue Injuries
06/24
12/24
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT00970164: Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis

Not yet recruiting
2/3
1600
US, Canada
Lacidofil, placebo
Washington University School of Medicine
Gastroenteritis, Child
07/14
12/14
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Active, not recruiting
2
191
Europe, Japan, US, RoW
Experimental drug, Placebo
Novartis Pharmaceuticals
Resistant Hypertension
07/24
08/24
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Recruiting
2
156
US
MHS-1031, Panosyl-isomaltooligosaccharide, Placebo
Microbiome Health Sciences, VBHRC Virginia Catalyst
Gastroesophageal Reflux
04/25
04/25
NCT05269628: Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Recruiting
2
166
US
Cannabidiol (CBD), Epidiolex®, Tetrahydrocannabinol (THC), Marinol®, dronabinol, Placebo CBD, Placebo THC
Tiffany J. Braley, MD, MS, National Center for Complementary and Integrative Health (NCCIH)
Multiple Sclerosis, Sleep, Pain
06/26
06/26
ACL SNNAP, NCT02980367 / 2006-002803-15: Trial: ACL Surgery Necessity in Non Acute Patients

Recruiting
N/A
320
Europe
Non-Surgical Management (Rehabilitation), Physical Therapy, Physiotherapy, Conservative Rehabilitation, Conservative Management, Surgical Management (Reconstruction), ACL Reconstruction, ACLR, ACL surgery, Anterior Cruciate Ligament Surgery, Surgical Management
University of Oxford
Anterior Cruciate Ligament Injury
11/21
03/22
NCT04196088: To Compare Artificial Intelligence Software Aided Adenoma Detection in Screening Colonoscopies Versus Standard Colonoscopy Without Artificial Intelligence Software Assistance in Participants Between 45 and 75 Years of Age

Recruiting
N/A
978
US
Ultivision Artificial Intelligence Software, No Artificial Intelligence Software enhancement
Docbot, Inc.
Colorectal Adenoma, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal SSA
11/21
12/21
EEDICF, NCT04149717: The Effect of Energy Drink Ingredients on Cardiovascular Function in Men and Women 18-39 Years Old

Recruiting
N/A
35
US
Energy Drink Ingredients and Exercise
Duquesne University
Cardiac Arrhythmia, Blood Pressure
12/22
03/23
NCT04106232: Microbiome Analysis of Constipated Versus Non-constipation Patients

Completed
N/A
30
US
No change in procedure except for specimen collection throughout procedure
HyGIeaCare, Inc.
Rome IV Functional Constipation
03/23
03/23
NCT05640583: Assessing Uniqueness of Inflammatory Bowel Disease Related Microbiome-derived Biomarkers

Completed
N/A
20
US
Hygieacare System
HyGIeaCare, Inc.
Irritable Bowel Disease
03/23
03/23
TEACH-PD CRCT, NCT03816111: Targeted Education ApproaCH to Improve Peritoneal Dialysis Outcomes Trial

Active, not recruiting
N/A
1500
RoW
TEACH-PD Training Curriculum, Current standard PD training
The University of Queensland, The HOME Network, Australia and New Zealand Dialysis and Transplant Registry, New Zealand Peritoneal Dialysis Registry
Kidney Disease, Chronic, Peritoneal Dialysis Catheter-Associated Peritonitis, Peritoneal Dialysis Catheter Exit Site Infection, Peritoneal Dialysis Catheter Tunnel Infection
03/25
04/25
NCT01191151: Web Based Orthopaedic Sports Medicine Registry

Recruiting
N/A
12500
Europe, Canada, US, RoW
Arthrex, Inc.
Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip
06/23
06/23
DDPP, NCT04141878: Dementia and Diabetes Prevention Program

Recruiting
N/A
400
US
Aerobic Exercise, Diet Skills
University of California, Davis, East Oakland Sports Center, Tice Creek Fitness Center
Diabetes, Dementia
12/23
06/24
NCT04932148: INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD)

Recruiting
N/A
372
Canada, RoW
Incremental HD, Conventional HD
The University of Queensland, Medical Research Future Fund, Queensland Health, Canadian Institutes of Health Research (CIHR)
Kidney Failure
08/26
08/26
Lassman, Andrew
NRG-BN007, NCT04396860: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Active, not recruiting
2/3
159
US
Contrast-enhanced Magnetic Resonance Imaging, CONTRAST ENHANCED MRI, Contrast-enhanced MRI, MRI With Contrast, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, NovoTTF-100A Device, NovoTTF-100A, NovoTTF-100A System, NovoTTF-100A system (Optune), NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI), NRG Oncology
Gliosarcoma, MGMT-Unmethylated Glioblastoma
04/23
03/25
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT04691960: A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging

Recruiting
2
36
US
Ketogenic Diet, Metformin
Weill Medical College of Cornell University
Glioblastoma
12/24
12/24
XPORT-GBM-029, NCT04421378: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Terminated
1/2
74
Canada, US
Selinexor, KPT-330, XPOVIO, Temozolomide (TMZ), Temodar, Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Karyopharm Therapeutics Inc
Glioblastoma Multiforme
07/23
07/23
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT02238496: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Completed
1
10
US
Cytoreductive surgery, Resection, Perifosine, AEZS-104/D-21266, KRX-0401, Temsirolimus, Torisel
Andrew B Lassman, MD, Pfizer, AEterna Zentaris
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
10/17
02/21
Mellinghoff, Ingo
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03581942: Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Active, not recruiting
1/2
18
US
Ibrutinib, Copanlisib
Memorial Sloan Kettering Cancer Center
Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
07/25
07/25
NCT02315326: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Recruiting
1/2
109
US
Ibrutinib, Imbruvica™, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine
Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC., Janssen Biotech, Inc.
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
12/26
12/26
Morgan, James
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT06137222: Prospective, Multicenter, RCT of the Tenex Ultrasound System

Not yet recruiting
N/A
148
US
Tenex TXB MicroTip Ultrasound system plus SOC, Standard of Care for diabetic foot ulcer
Tenex Health Inc., Trice Medical
Diabetic Foot Ulcer
03/24
12/25
Lindhorst, Scott
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Active, not recruiting
3
270
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Recruiting
3
360
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
WF-1801, NCT03475186: Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Active, not recruiting
2
75
US, RoW
Ramipril, Altace, Tritace
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
07/24
07/24
NCT03173950: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Recruiting
2
180
US
Nivolumab
National Cancer Institute (NCI)
Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
04/26
04/27
NCT04609046: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Recruiting
1
47
US
Bone Marrow Aspiration and Biopsy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Lumbar Puncture, LP, Spinal Tap, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
National Cancer Institute (NCI)
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
05/25
05/25
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
950
Europe, Canada, Japan, US, RoW
Optune®
NovoCure GmbH
Glioblastoma Multiforme
08/24
08/26
Roque, Dario R
NRG-GY033, NCT06169124: Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Suspended
2
37
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Chest Radiography, Chest X-ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Exemestane, Aromasin, FCE-24304, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI), NRG Oncology
Adult Ovarian Granulosa Cell Tumor
05/27
05/27
NCT05456685: IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
114
Europe, Canada, US, RoW
Mirvetuximab soravtansine, IMGN853, MIRV, Carboplatin
ImmunoGen, Inc.
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
12/26
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
Cachia, David
NCT05488873: A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy

Recruiting
2
60
US
WST-057 Active, Active, Placebo
WinSanTor, Inc
Chemotherapy-induced Peripheral Neuropathy
04/24
05/24
NCT04762069: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
NRG-BN010, NCT04729959: Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Recruiting
2
53
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Fractionated Stereotactic Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Tocilizumab, Actemra, IL-6 receptor monoclonal antibodies: tocilizumab, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA, R-1569, RoActemra
National Cancer Institute (NCI), NRG Oncology
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
06/25
06/25
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
950
Europe, Canada, Japan, US, RoW
Optune®
NovoCure GmbH
Glioblastoma Multiforme
08/24
08/26
Manager, Program
NCT05268666: A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

Recruiting
1/2
126
US
JBI-802
Jubilant Therapeutics Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
12/24
08/25
ENHANCE, NCT05866471: Pairing Psilocybin With Transcutaneous Auricular Vagus Nerve Stimulation

Not yet recruiting
1
108
US
Psilocybin, Psilocybine, Psilocibin, Filament Health Psilocybin, PEX010, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Sham taVNS, Treatment as Usual (TAU)
University of Wisconsin, Madison, Tiny Blue Dot Foundation
Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
07/27
10/27
IMPACT, NCT04330833: Informational Meetings for Planning and Coordinating Treatment

Recruiting
N/A
166
US
Novel Communication Intervention, Enhanced Usual Care Parent Education
Indiana University, National Cancer Institute (NCI)
End of Life, Communication, Cancer Metastatic
04/25
04/25
MAC:H-TAD, NCT04005976: Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

Recruiting
N/A
5000
US
The University of Texas Health Science Center, Houston
Aortic Aneurysm, Aortic Dissection, Aortic Diseases
01/37
01/37
Hunt, Lindsay
TIGeR-PaC, NCT03257033: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Recruiting
3
320
Europe, US
Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath, RenovoCath RC120
RenovoRx
Locally Advanced Pancreatic Cancer
09/22
09/23
Kaczmar, John
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
NCT03811015: Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Recruiting
3
636
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
01/27
01/27
NCT03944941: Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Active, not recruiting
2
60
US
Avelumab, Cetuximab
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
11/24
12/24
VERSATILE002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

Checkmark Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Active, not recruiting
2
95
Europe, US
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp., Merck Sharp & Dohme LLC
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
06/25
06/25
NCT05366166: Pembrolizumab Plus Olaparib in LA-HNSCC

Recruiting
2
45
US
Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, AZD-2281, MK-7339, KU0059436, Cisplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-platinum, IMRT (intensity modulated radiation therapy)
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of Head and Neck
10/25
10/26
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc.
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
11/24
11/24
NRG-HN010, NCT05408845: Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recruiting
2
116
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Questionnaire Administration, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
NRG Oncology, National Cancer Institute (NCI)
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
07/28
07/28
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
NCT03245489: Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
1
20
US
Pembrolizumab, Keytruda, Clopidogrel, Plavix, acetylsalicylic acid, ASA, aspirin
Medical University of South Carolina
Head and Neck Cancer
06/24
09/24
NCT04883645: Topical Aldara (Imiquimod) for Oral Cancer

Active, not recruiting
1
15
US
Imiquimod 5% Cream
Medical University of South Carolina
Oral Cancer
06/23
09/24
KEYNOTE-E28, NCT04429542: Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Recruiting
1
292
Canada, US
BCA101, Pembrolizumab
Bicara Therapeutics, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
12/26
06/27
Greenwell, Irl Brian
NCT03478514: Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

Active, not recruiting
2
39
US
Palbociclib, Ibrance; PD-0332991, Ibrutinib, Imbruvica
Alliance Foundation Trials, LLC., Pfizer
Mantle Cell Lymphoma, B Cell Lymphoma
06/25
12/25
NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting
2
360
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Bendamustine, SDX-105, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Liver Lymphoma, Mantle Cell Lymphoma
12/24
03/25
A051902, NCT04803201: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Recruiting
2
170
US
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
06/25
01/26
NCT05321147: Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Completed
1
20
US, RoW
lacutamab, IPH4102
Innate Pharma
Peripheral T Cell Lymphoma
11/23
02/24
Myers, Lindsey
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
Kinsey, Jennifer
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28

Download Options